Overview

Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction

Status:
Unknown status
Trial end date:
2019-05-30
Target enrollment:
0
Participant gender:
Male
Summary
Irreversible electroporation (IRE) is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane. It has been verified to be safe on the treatment of prostate, lung, liver and kidney masses. The present is a randomized, controlled trial, with a main purpose of looking into the safety and feasibility of irreversible electroporation for patients with benign prostatic obstruction.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Changhai Hospital
Criteria
Inclusion Criteria:

1. Male, 45 years or older.

2. The presence of voiding symptoms, i.e. slow stream, intermittent stream, hesitancy,
straining, etc.

3. Qmax ≥ 5 mL/s and ≤ 15 mL/s with minimum voided volume of 125 mL or more during flow
study.

4. The presence of bladder outlet obstruction during pressure-flow study.

5. International Prostatic Symptom Score (IPSS) ≥ 12 at screening.

6. Prostate volume ≥ 30 ml (using a transrectal ultrasound approach).

7. Total serum prostatic specific antigen (PSA) ≥ 1.5 ng/mL and ≤ 10 ng/mL at screening.

8. Subject is able to communicate and complete the questionnaires properly.

9. Written informed consent.

Exclusion Criteria:

1. Diagnosis or suspicion of bladder, prostate, urethral or pelvic tumor.

2. Patients with arrhythmia or history of cardiac pacemaker implantation.

3. Known lower urinary tract or pelvic surgical history.

4. Voiding symptoms as a result of urethral stricture, stone diseases, chronic
prostatitis, space-occupying lesions etc.

5. Known neurogenic or congenital lower urinary tract dysfunction.

6. Rigid or flexible cystoscopy examination within the past 7 days at screening.

7. Existence of anatomical abnormalities of the urinary tract (e.g. diverticulum of the
bladder or urethra, ectopic ureteral orifice etc.).

8. The presence of acute conditions, such as, urinary tract infection, fever, heart
failure etc.

9. Patients with poor compliance or cognitive competence.